2026-01-08
The European Union has, as an institution, become associated in many European and American minds with strict regulation and thick bureaucracy. Rasheed Griffith has a good piece of pushback , insisting that the EU might b…
Griffith’s essay pairs well with this long X post by Seán Keyes , executive director of Progress Ireland, listing ideas for helping the Republic of Ireland get more housing, infrastructure, and energy production. Some of…
Meanwhile, this Boston Globe editorial on housing, continues their marked increases in pro-housing coverage of the last several years.
Daniel Stid, writing for his substack , points out that there is a mismatch between how much governing happens at the state level (maybe most of it?) and the level of civil infrastructure (think tanks and other policy su…
The FDA recently announced it would shift from requiring two clinical trials to one. Why the change? In his Substack , Adam Kroetsh points out things have been moving in this direction a long time (the FDA has had the au…
One reason clinical trials can take a long time is because it can take a long time to see how a patient’s condition turns out - some diseases have a slow progression. A good “surrogate endpoint” is a biomarker that relia…
More Adam Kroetsh! Writing for Asterisk , he puts the FDA’s current trust woes in a longer context: how did the FDA achieve its trusted status in the first place? Kroetsch also reminds us of many of the achievements of t…
In case you missed it over the holidays, the Institute for Progress responded to OSTP’s RFI on accelerating science with a wide-ranging set of recommendations. In addition to some metascientific mainstays — like fast gra…
As an aside, if we needed a reminder about why scientific progress and clinical trial speed matters, Abundance and Growth Fund team member Saloni Dattani gives us a tour of medical breakthroughs of 2025 on her substack.